Hemogenyx Pharmaceuticals Plc

LSE:HEMO Stock Report

Market Cap: UK£13.0m

Hemogenyx Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Hemogenyx Pharmaceuticals's earnings have been declining at an average annual rate of -28.1%, while the Biotechs industry saw earnings growing at 7.7% annually.

Key information

-28.1%

Earnings growth rate

-1.8%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth raten/a
Return on equity-171.6%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Is Hemogenyx Pharmaceuticals (LON:HEMO) In A Good Position To Deliver On Growth Plans?

Aug 21
Is Hemogenyx Pharmaceuticals (LON:HEMO) In A Good Position To Deliver On Growth Plans?

Will Hemogenyx Pharmaceuticals (LON:HEMO) Spend Its Cash Wisely?

May 04
Will Hemogenyx Pharmaceuticals (LON:HEMO) Spend Its Cash Wisely?

We Think Hemogenyx Pharmaceuticals (LON:HEMO) Needs To Drive Business Growth Carefully

Jan 06
We Think Hemogenyx Pharmaceuticals (LON:HEMO) Needs To Drive Business Growth Carefully

Hemogenyx Pharmaceuticals (LON:HEMO) Has Debt But No Earnings; Should You Worry?

Oct 09
Hemogenyx Pharmaceuticals (LON:HEMO) Has Debt But No Earnings; Should You Worry?

Revenue & Expenses Breakdown

How Hemogenyx Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:HEMO Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-530
31 Mar 240-640
31 Dec 230-750
30 Sep 230-760
30 Jun 230-780
31 Mar 230-660
31 Dec 220-450
30 Sep 220-340
30 Jun 220-330
31 Mar 220-430
31 Dec 210-530
30 Sep 210-520
30 Jun 210-520
31 Mar 210-320
31 Dec 200-220
30 Sep 200-220
30 Jun 200-220
31 Mar 200-220
31 Dec 190-120
30 Sep 190-220
30 Jun 190-220
31 Mar 190-220
31 Dec 180-220
30 Sep 180-210
30 Jun 180-310
31 Mar 180-310
31 Dec 170-210
31 Dec 160000
31 Dec 150000

Quality Earnings: HEMO is currently unprofitable.

Growing Profit Margin: HEMO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: HEMO is unprofitable, and losses have increased over the past 5 years at a rate of 28.1% per year.

Accelerating Growth: Unable to compare HEMO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HEMO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: HEMO has a negative Return on Equity (-171.61%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 12:59
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hemogenyx Pharmaceuticals Plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution